This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cauley, J. A. Articles by Ettinger, B. Search for Related Content PubMed PubMed Citation Articles by Cauley, J. A. Articles by Ettinger, B.

Timing of Estrogen Replacement Therapy for Optimal Osteoporosis Prevention

Department of Epidemiology (J.A.C., J.M.Z.), University of Pittsburgh, Pittsburgh, Pennsylvania 15261; Department of Internal Medicine and Epidemiology (K.E.E.), University of Minnesota, Minneapolis, Minnesota 55417; Department of Epidemiology and Biostatistics (D.C.B.), University of California, San Francisco, San Francisco, California 94105; and Kaiser Permanente Medical Care Program (B.E.), Oakland, California 15261

Address all correspondence and requests for reprints to: Jane A. Cauley, Ph.D., University of Pittsburgh, Department of Epidemiology, Pittsburgh, Pennsylvania 15261.

Abstract

To determine whether estrogen initiated at age 60 yr or later reduces rates of bone loss and fracture incidence, we performed a prospective cohort study of 6910 nonosteoporotic women, 65 yr of age or older. Estrogen use, medical history, lifestyle, and anthropometric data were obtained by questionnaire, interview and examination. We identified five patterns of estrogen use: never users (67%); past early users (started under age 60 yr with no current use; 23%); past late users (started at age 60 or later with no current use; 2%); current early users (started under age 60 yr with use both at baseline and 6 yr later; 6.7%); and current late users (started at age 60 or later with use at baseline and 6 yr later; 1.5%). Bone mineral density was measured at the total hip twice, an average of 3.5 yr apart, and at the calcaneus, an average of 5.7 yr apart. Incident nonspine fractures were validated by radiographic report. Bone mineral density was significantly higher among current users, compared with never and past users. The annual rate of hip bone loss was significantly lower in current early users (-0.22%/yr) and current late users (-0.35%/yr) in comparison with never users (-0.6%/yr), past early users (-0.6%/yr), and past late users (-0.72%/yr). During an average of 11.0 yr of follow-up, 1953 nonspine fractures were confirmed. The multiple-adjusted relative risk of nonspine fracture was 0.63 (95% confidence interval 0.51–0.78) among current early users and 0.75 (0.50–1.12) among current late users, compared with never users. Early initiation and long-term continuation of estrogen is associated with a reduction in the risk of nonspine fractures, and initiation at or after age 60 yr with long-term continuation may also be associated with a reduced fracture risk.

This article has been cited by other articles:

				S. M Ott Making decisions about hormone replacement therapy: Bisphosphonates should not be recommended for women aged 50 BMJ, June 19, 2003; 326(7403): 1398 - 1398. [Full Text]

				H. D. Nelson, J. Rizzo, E. Harris, J. Cauley, K. Ensrud, D. C. Bauer, E. Orwoll, and for the Study of Osteoporotic Fractures Research G Osteoporosis and Fractures in Postmenopausal Women Using Estrogen Arch Intern Med, November 11, 2002; 162(20): 2278 - 2284. [Abstract] [Full Text] [PDF]

				H. D. Nelson Assessing Benefits and Harms of Hormone Replacement Therapy: Clinical Applications JAMA, August 21, 2002; 288(7): 882 - 884. [Abstract] [Full Text] [PDF]

				Bone Density and Timing of Hormone Replacement Therapy Journal Watch (General), January 18, 2002; 2002(118): 5 - 5. [Full Text]